ACELYRIN reports FY 2023 net loss of $381.6M; cash $721.3M; pipeline progress with izokibep and lonigutamab

ACELYRIN, Inc.

Net loss $381.6M in 2023 vs $64.8M in 2022; R&D expenses $355.9M including $123.1M IPR&D from ValenzaBio acquisition.
Cash, equivalents and marketable securities $721.3M expected to fund operations into 2026 through late-stage registrational studies.
Positive Phase 1/2 data for lonigutamab (subcutaneous anti-IGF-1R) in thyroid eye disease with rapid proptosis improvements at 3 weeks.
Phase 2b/3 trial of izokibep met primary endpoint ACR50 at 16 weeks with high statistical significance in psoriatic arthritis; HS Phase 3 topline data expected H2 2024.
Appointed Agnes Lee as SVP IR and Corporate Communications; Lynn Tetrault joined Board in December 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACELYRIN, Inc. reported the full year ended December 31, 2023 results: net income Net loss for the full year ended December 31, 2023 was $381.6 million, compared to $64.8 million for 2022..

Period: the full year ended December 31, 2023
Net income: Net loss for the full year ended December 31, 2023 was $381.6 million, compared to $64.8 million for 2022.
Result: reported results

Exact text from the filing

On March 28, 2024, ACELYRIN, INC. (the " Company ") issued a press release announcing its financial results for the year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001962918-24-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.